Suven Life Sciences Limited SUVENshare price and chart
Suven Life Sciences closed at ₹265.65 on 18 November 2026, down 1.12% on the day. The 52-week range is ₹124.11 to ₹403.35.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on SUVEN
Real prices, every charge counted. Pick one or write your own.Suven Life Sciences provides scientific research and technical services, 100% of its turnover, to pharmaceutical and life sciences companies. Exports are 70% of turnover.
Healthcare Services
Pharmaceutical research services
Pharma and life sciences companies
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 18 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Healthcare Services · 49 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026, sales rose 30.4% from a year earlier to ₹1.2 cr and the loss was ₹107 cr against ₹77.3 cr a year earlier.
- No borrowings at the FY26 balance sheet.
- No promoter shares were pledged at the end of September 2026.
- Reported a loss in FY24 and FY25 and FY26.
- Operating margin fell from -933.3% in FY23 to -4007.0% in FY26.
- Profit before interest covered interest -1380.5 times in FY26 (₹0 cr of interest).
- Return on equity stayed under 10% from FY24 to FY26 (highest -32.6%).
- Promoter holding fell 4.8 points over 5 quarters (70.27% to 65.47%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Share price reaction to resultsWhat the share price did around each recent quarterly result.
Over the last 19 results, the share rose on 10 and fell on 9, and moved by 3% or more on 9.
Q1 FY27: results filed 6 Aug 2026. The share went from its close on 5 Aug 2026 to its close on 7 Aug 2026 -2.50%.
Dividend historyCash the company has paid per share, year by year.
2019 paid ₹1.50 per share, about ₹565 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 10 years this compounded at +42.8% a year. The last twelve months were up +53.8%. Price only, before dividends.
Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 8 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.
Last 18 monthsRecent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Healthcare Research Analytics & Technology. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Revenue and profit, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹0.0 as profit. Other income added ₹195.8.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearCash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash fell by ₹7 Cr, after ₹5 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | 14.4% | -13.3% | -42.7% | 6.0% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | -933% | -1094% | -2494% | -4007% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | -876% | -898% | -2399% | -3892% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | -31.5% | -32.6% | -84.6% | -78.8% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | -31.4% | -32.8% | -84.6% | -78.8% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | -393.3x | -529.5x | · | -1380.5x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Healthcare Services| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP Apollo Hospitals Enterprise Limited | 1.27 L cr | 56.6x | 12.0x | 21.5% | 20.7% | 0.50 | 8.4% | +20.8% | 0.23% |
| MAXHEALTH Max Healthcare Institute Limited | 99,555 cr | 72.0x | 8.8x | 14.3% | 14.4% | 0.33 | 15.1% | +20.3% | 0.20% |
| MANIPALHOS Manipal Health Enterprises Limited | 90,610 cr | - | 5.4x | - | - | 0.34 | - | - | 0.00% |
| ASTERDM Aster DM Quality Care Limited | 63,719 cr | 101.0x | 8.2x | 10.1% | 14.8% | 0.43 | 8.7% | +136.3% | 0.41% |
| FORTIS Fortis Healthcare Limited | 59,910 cr | 57.7x | 5.7x | 11.0% | 13.5% | 0.29 | 10.7% | +17.3% | 0.13% |
| NH Narayana Hrudayalaya Ltd. | 38,651 cr | 44.7x | 7.7x | 19.7% | 16.0% | 0.99 | 8.4% | +73.0% | 0.24% |
| MEDANTA Global Health Limited | 38,626 cr | 62.4x | 8.9x | 15.0% | 17.9% | 0.16 | 12.1% | +33.6% | 0.03% |
| LALPATHLAB Dr. Lal Path Labs Ltd. | 32,989 cr | 56.3x | 12.0x | 21.5% | 29.1% | 0.00 | 19.4% | +19.6% | 0.89% |
| KIMS Krishna Institute of Medical Sciences Limited | 31,878 cr | 145.4x | 8.1x | 9.7% | 9.9% | 0.83 | 4.3% | +39.9% | 0.00% |
| SYNGENE Syngene International Limited | 17,552 cr | 93.9x | 3.6x | 6.6% | 9.5% | 0.01 | 5.3% | -8.6% | 0.29% |
| AGARWALEYE Dr. Agarwal's Health Care Limited | 17,421 cr | 101.8x | 7.8x | 8.3% | 15.2% | 0.09 | 8.7% | +31.4% | 0.00% |
| VIJAYA Vijaya Diagnostic Centre Limited | 15,796 cr | 77.5x | 14.9x | 19.7% | 30.3% | 0.00 | 22.4% | +26.7% | 0.13% |
| INDGN Indegene Limited | 15,782 cr | 38.3x | 4.7x | 13.9% | 18.9% | 0.00 | 9.9% | +39.5% | 0.34% |
| RAINBOW Rainbow Childrens Medicare Limited | 12,777 cr | 43.7x | 7.5x | 17.9% | 27.8% | 0.00 | 15.5% | +23.2% | 0.28% |
| METROPOLIS Metropolis Healthcare Limited | 11,703 cr | 52.1x | 7.1x | 13.4% | 19.6% | 0.01 | 12.7% | +15.8% | 0.35% |
| YATHARTH Yatharth Hospital & Trauma Care Services Limited | 10,513 cr | 55.2x | 5.6x | 9.9% | 12.4% | 0.24 | 12.2% | +54.4% | 0.05% |
| PARKHOSPS Park Medi World Limited | 10,282 cr | 37.0x | 4.8x | 13.0% | 17.7% | 0.20 | 14.7% | - | 0.00% |
| JLHL Jupiter Life Line Hospitals Limited | 9,494 cr | 50.7x | 5.8x | 13.7% | 16.0% | 0.36 | 11.4% | +16.0% | 0.07% |
| HCG Healthcare Global Enterprises Limited | 8,948 cr | 844.1x | 6.6x | 1.9% | 9.4% | 0.52 | 0.8% | +13.1% | 0.00% |
| THYROCARE Thyrocare Technologies Limited | 8,016 cr | 56.0x | 14.5x | 28.7% | 37.8% | 0.00 | 15.4% | +25.1% | 1.39% |
| SUVEN Suven Life Sciences Limited | 7,506 cr | - | 16.6x | -78.8% | -78.8% | 0.00 | - | +30.4% | 0.00% |
| NEPHROPLUS Nephrocare Health Services Limited | 6,567 cr | 50.3x | 5.5x | 6.9% | 13.4% | 0.07 | 11.5% | - | 0.00% |
| ARTEMISMED Artemis Medicare Services Limited | 5,436 cr | 47.4x | 5.5x | 11.6% | 14.8% | 0.24 | 10.0% | +13.2% | 0.13% |
| INDRAMEDCO Indraprastha Medical Corporation Limited | 3,282 cr | 17.1x | 4.0x | 27.5% | 37.7% | 0.00 | 12.3% | +8.3% | 1.12% |
| KMCSHIL K M C Speciality Hospitals (India) Limited | 3,220 cr | 52.6x | - | - | - | - | 17.5% | +24.1% | 0.00% |
| DRAGARWQ Dr Agarwals Eye Hospital Limited | 2,819 cr | 37.0x | - | - | - | - | 15.3% | +22.3% | 0.07% |
| VIMTALABS Vimta Labs Limited | 2,087 cr | 25.9x | 4.3x | 18.6% | 24.8% | 0.03 | 18.7% | +9.9% | 0.43% |
| SURAKSHA Suraksha Diagnostic Limited | 1,813 cr | 43.3x | 6.6x | 13.8% | 24.8% | 0.02 | 11.9% | +25.8% | 0.14% |
| KRSNAA Krsnaa Diagnostics Limited | 1,659 cr | 16.9x | 1.6x | 10.9% | 12.7% | 0.57 | 11.1% | +31.5% | 0.39% |
| SHALBY Shalby Limited | 1,285 cr | 33.5x | 1.3x | 3.5% | 6.7% | 0.53 | 3.2% | +9.7% | 0.00% |
| GKSL Gujarat Kidney And Super Speciality Limited | 1,196 cr | 55.6x | 4.5x | 6.6% | 8.6% | 0.06 | 16.2% | +194.6% | 0.00% |
| 3BBLACKBIO 3B Blackbio Dx Limited | 1,134 cr | 19.1x | - | - | - | - | 35.4% | +42.4% | 0.38% |
| GPTHEALTH GPT Healthcare Limited | 1,104 cr | 21.2x | 3.9x | 16.3% | 23.1% | 0.05 | 10.2% | +14.1% | 0.74% |
| HEALTHX Health X Platform Limited | 874 cr | - | 1.4x | -0.2% | - | 0.04 | -1.4% | +60.7% | 0.00% |
| CREDENT Credent Connect N Care Limited | 843 cr | - | 5.9x | - | - | 0.15 | - | - | 0.00% |
| UNIHEALTH Unihealth Hospitals Limited | 785 cr | - | 7.6x | - | 16.2% | 0.13 | - | - | 0.00% |
| ONEGLOBAL One Global Service Provider Limited | 755 cr | 12.1x | - | - | - | - | 14.1% | -50.8% | 0.26% |
| GAUDIUMIVF Gaudium IVF and Women Health Limited | 709 cr | 28.1x | 4.3x | 16.1% | 20.4% | 0.03 | 20.8% | - | 0.00% |
| MOMSBELIEF Rays of Belief Limited | 594 cr | - | 3.9x | - | - | 0.15 | - | - | 0.00% |
| CHANDAN Chandan Healthcare Limited | 583 cr | - | 3.4x | - | 22.4% | 0.32 | - | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.1 | +10.0 | -9.8 | +60.9 | +31.8 | +0.5 | +9.4 | +27.7 | -18.3 | -19.2 | +7.0 | · | +66.5% 11m |
| 2025 | +0.6 | -19.1 | +9.1 | +12.2 | +92.0 | +0.5 | +10.7 | -21.4 | -4.5 | -3.3 | -12.9 | -3.4 | +30.0% |
| 2024 | +34.1 | -5.5 | -2.3 | +10.4 | -16.2 | +13.6 | +36.6 | -0.8 | -1.4 | -10.7 | +3.3 | -1.4 | +58.4% |
| 2023 | -9.7 | -9.9 | -12.9 | +17.8 | -3.0 | +14.2 | +0.6 | +1.2 | +10.2 | +14.9 | +3.1 | -4.0 | +18.0% |
| 2022 | +0.1 | -11.1 | +16.9 | -5.8 | -9.0 | -11.6 | +2.5 | +1.3 | -2.5 | -7.2 | +3.9 | +8.5 | -16.6% |
| 2021 | -21.8 | +19.6 | -16.6 | +45.6 | -8.7 | -6.4 | -6.4 | +1.0 | +12.3 | +3.1 | -8.3 | +0.9 | -1.6% |
| 2020 | +52.1 | +165.3 | -65.5 | +114.7 | -25.8 | +21.4 | -8.4 | +30.9 | +1.6 | -8.1 | +0.3 | +94.9 | +489.7% |
| 2019 | -14.5 | +24.4 | +8.3 | +1.5 | +2.8 | -0.4 | -16.0 | +14.0 | +7.2 | +1.6 | +11.3 | -2.5 | +35.6% |
| 2018 | +5.7 | -12.6 | -10.9 | +7.3 | +6.4 | +8.8 | +10.7 | +21.4 | -3.5 | -10.4 | -0.2 | -6.1 | +11.4% |
| 2017 | +1.3 | -1.9 | -3.8 | +9.3 | +3.8 | -8.5 | -2.9 | -1.9 | +8.2 | +21.4 | -8.5 | +3.5 | +17.6% |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2024-01-11 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 14,28,543 | ₹121.70 | ₹17.39 Cr |
| 2024-01-11 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 14,28,543 | ₹121.82 | ₹17.40 Cr |
| 2023-09-13 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 15,34,944 | ₹78.20 | ₹12.00 Cr |
| 2023-09-13 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 15,34,944 | ₹78.12 | ₹11.99 Cr |
| 2021-04-23 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 6,40,960 | ₹109.97 | ₹7.05 Cr |
| 2021-04-23 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 6,40,960 | ₹109.64 | ₹7.03 Cr |
| 2020-12-17 | ALPHA LEON ENTERPRISES LLP · bulk | BUY | 6,56,474 | ₹104.94 | ₹6.89 Cr |
| 2020-12-17 | ALPHA LEON ENTERPRISES LLP · bulk | SELL | 6,27,462 | ₹105.08 | ₹6.59 Cr |
- Board outcomeOutcome of Board Meeting5 Nov 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
- Board outcomeOutcome of Board Meeting6 Aug 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
- Board outcomeOutcome of Board Meeting13 May 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
- Board outcomeOutcome of Board Meeting13 May 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
- Board outcomeOutcome of Board Meeting29 Jan 2026
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
- Board outcomeOutcome of Board Meeting11 Nov 2025
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
- Board outcomeOutcome of Board Meeting13 Aug 2025
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
- Integrated Filing- Financial24 Jan 2025
Integrated Filing- Financial
- Financial Result Updates24 Jan 2025
Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test SUVEN. “Buy SUVEN when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free